ATR-CM processing options

Treatment for ATR-CM has historically been the management of symptoms. However, until 2019, the United States Food and Drug Administration (FDA) did not approve any treatment for the disease. Since then, two other drugs have received approval from the FDA.

Jump at the main dishes to remember.

What processing options are available for ARTR-CM?

Amvuttra

Amvuttra (Vutrisiran) is a medication used to treat ATR-CM and polyneuropathy caused by hereditary amyloidosis of transthyretin.

Here are the details highlighted from AMVUTTRA:

• The drug was approved by the FDA in 2022 and no generic form is currently available.
• Amvuttra blocks the formation of transthyretine protein.
• Amvuttra targets liver cells where transthyretin is manufactured, thereby reducing transhyretine deposits.
• Side effects include: pain in joints, hands and feet, low levels of vitamin A and shortness of breath.
• People with low vitamin A resulting from the drug will have to take a vitamin A supplement.
• Amvuttra is administered by a subcutaneous injection once every three months.

Atttruby

ATTRUPY (Acoramidis) is an oral drug used to treat ATR-CM.

Below you will find the important facts on Attrup:

• Attrup was approved by the FDA in 2024 and has no generic shape.
• Stabilizes transhyretine by binding the binding sites of thyroxine. This slows down the formation of protein deposits in the heart.
• Side effects include diarrhea and upper abdominal pain.
• The drug is generally taken twice a day.

Wishing

Vyndamax (Tafamidis) is an oral prescription medication used to treat ATR-CM.

Important facts on Vyndamax include:

• Approved by the FDA in 2019, no generic form is currently available.
• Vyndamax stabilizes the transthyretin protein, which prevents deposits from forming in the heart.
• The most common side effect is diarrhea.
• Vyndamax is generally taken once a day.

Vyndakel

Vyndaqel (Tafamidis Meglumin) is a drug used to treat ATR-CM. It contains the same active ingredient as Vyndamax, but Vyndaqel has the salt of Tafamidis Méglumine micronized.

Here are the important vyndaqel strong points:

• It was approved by the FDA for ASTR-CM treatment in 2019.
• Vyndaqel works by focusing and stabilizing the protein of transthyretin, which slows down the accumulation of deposits in the heart muscle.
• The most reported side effect is diarrhea.
• The dosage is four capsules once a day.
• Vyndaqel and Vyndamax are not interchangeable. However, a supplier can change patients from one medication to another if indicated.

Manage heart failure

People with ATR-CM can develop heart failure from cardiomyopathy. However, management of heart failure in people with ATR-CM is different from heart failure without ATR-CM.

As in most cases of heart failure, diuretics are still used in people with ATR-CM. However, ECA inhibitors, beta-blockers, angiotensin receptor blockers and angiotensine-neprideine receptor inhibitors, which are generally used in people with heart failure, are not well tolerated in people with ATR-CM.

Manage cardiac arrhythmias

According to an article in 2023 of the Journal of the American College of Cardiology, 70% of people with ATR-CM also had episodes of atrial fibrillation (AF or AFIB). There is a strong occurrence of blood clots in people with FA; Therefore, anticoagulant treatment is often recommended.

The treatment of an antiarrhythmic varies depending on the patient and his response. It ranges from antiarrhythmic drugs to removal surgery to implanting the cardiac stimulator.

Types of ATR-CM

There are two types of ATR-CM: wild and hereditary type. The wild-type ATT-CM is a more commonly observed age in older men.

Hereditary Artr-CM works in families and is caused by a genetic mutation. Hereditary anti-CM is more often seen in people of:

• Brazil
• Portugal
• Suede
• Japan

ATR-CM symptoms

ATR-CM symptoms often overlap those of other health problems or can be vague. This makes a difficult diagnosis. You will find below the symptoms associated with the ATR-CM:

• Shortness of breath
• Cough and whistling breathing
• Palpitations
• Dizziness
• Confusion
• Swelling in the lower limbs
• Increase in heart rate
• Abdominal bloating
• Orthopneous
• Aroxysical night dyspnea

Long -term results

ARTR-CM is a type of cardiomyopathy that can cause heart failure if it is not treated. Its symptoms imitate other conditions, which makes diagnosis difficult. As a result, Astr-CM often has a bad prognosis and a reduced life expectancy. According to a review in 2022, life expectancy is generally two to five years after a diagnosis of attractive-CM.

Main to remember

• Historically, the treatment of the ATRT-CM had only been concentrated on the relief of symptoms, and not really the treatment of the disease.
• From now on, several prescription treatments are available that can slow the progression of the ATR-CM and minimize its heart effects.
• Talk to a health care provider if you think you have an atr-cm or if it works in your family.